CSRP2 promotes the glioblastoma mesenchymal phenotype via p130Cas-mediated NF-κB and MAPK pathways
Our findings demonstrate that CSRP2 promotes GBM malignancy including PMT and temozolomide resistance through activating p130Cas-mediated NF-κB and MAPK signaling pathways. Inhibiting CSRP2 function, including using MTO, may become a novel therapeutic approach for GBM.
Authors
- Sifang Chen (ORCID: https://orcid.org/0000-0001-5198-1361)
- Zhe Shen (ORCID: https://orcid.org/0000-0003-0604-7558)
- Jianyao Mao
- Yun‐wu Zhang (ORCID: https://orcid.org/0000-0002-7152-7630)
- Jiawei He (ORCID: https://orcid.org/0000-0003-1636-1823)
- Hanwen Lu (ORCID: https://orcid.org/0000-0003-1552-116X)
- Wanhong Han
- Wenhua Li (ORCID: https://orcid.org/0000-0002-9457-6662)
- Liang Zhang (ORCID: https://orcid.org/0000-0003-4528-2403)
- Zhanxiang Wang (ORCID: https://orcid.org/0000-0003-0405-6194)
- Xīn Gào (ORCID: https://orcid.org/0000-0003-0108-6961)
- Wentao Zhao (ORCID: https://orcid.org/0000-0003-4787-5245)
- Jian Meng (ORCID: https://orcid.org/0000-0002-2434-0697)
- Bingchang Zhang (ORCID: https://orcid.org/0000-0002-7655-7257)
- Wenpeng Zhao (ORCID: https://orcid.org/0009-0006-8811-8418)
- Hao Xu (ORCID: https://orcid.org/0000-0003-0054-9709)
- Zhangyu Li (ORCID: https://orcid.org/0000-0003-1242-3580)
- Guowei Tan (ORCID: https://orcid.org/0000-0003-4174-0382)
- Ziqian Tang
- Ping Zhong
- Bosen Liu (ORCID: https://orcid.org/0009-0000-2757-9241)
- Chengtian Gao
Institutions
- University of Science and Technology of China (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1186/s13046-025-03484-7
- Citations
- 1
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- National Natural Science Foundation of China